Xudong Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xudong Shi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Kai Gao
CAMS & PUMC, NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Science, National Human Diseases Animal Model Resource Center, National Center of Technology Innovation for Animal Model, State Key Laboratory of Respiratory Health and Multimorbidity
5 shared publications- Ran Gao
NHC Key Laboratory of Human Disease Comparative Medicine Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases Institute of Laboratory Animal Sciences Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC) Beijing China
4 shared publications Bao Liu
Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
1 shared publicationBowen Guan
CAMS & PUMC, NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Science, National Human Diseases Animal Model Resource Center, National Center of Technology Innovation for Animal Model, State Key Laboratory of Respiratory Health and Multimorbidity
1 shared publicationGuoxin Zhang
Key Laboratory of Human Disease Comparative Medicine, National Health Commission of China (NHC), Institute of Laboratory Animal Science, Peking Union Medicine College, Chinese Academy of Medical Sciences, No. 5 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
1 shared publicationHao Huang
Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) & Comparative Medicine Centre, Peking Union Medical Collage (PUMC), No. 5 Panjiayuan Nanli, Chaoyang District, Beijing 10021, PR China
1 shared publication
Latest Publications
- 16 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
Subcapsular Sinus Macrophage Transcytosis Enables Efficient Intralymphnode mRNA Delivery
Lymph node (LN)-targeted mRNA vaccines hold promise for cancer immunotherapy, but their efficacy is constrained by limited parenchymal delivery imposed by the lymphatic endothelial barrier of the subcapsular sinus (SCS). The SCS is populated by macrophages that efficiently capture pathogens, raising the question of whether this innate surveillance mechanism can be repurposed for vaccine transport─provided internalized nanoparticles can be rerouted from lysosomal degradation toward transcytosis. Here, we show that yeast cell wall–coated lipid nanoparticles (YCW-LNPs) reprogram SCS macrophages to mediate efficient transcytosis, enabling active delivery into the LN parenchyma and achieving approximately 21-fold higher LN accumulation than unmodified LNPs. Co-encapsulating ovalbumin (OVA) mRNA and the STING agonist MSA-2, YCW-LNPs preferentially accumulate in LNs, drive robust mRNA expression (14.5-fold and 7.4-fold higher than free mRNA and unmodified LNPs, respectively), and concurrently activate the STING pathway to amplify antigen-specific immune responses. In intradermal and lung-metastatic B16-OVA melanoma models, YCW-LNPs achieves marked tumor inhibition (up to 99.0%), prolong survival, and induce durable immune memory protecting mice against tumor rechallenge 60 days after treatment. This pathogen-inspired strategy converts SCS macrophages from degradative sinks into active transporters, offering a generalizable platform for delivering mRNA vaccines and immunomodulators to the LN parenchyma.
- 16 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
Subcapsular Sinus Macrophage Transcytosis Enables Efficient Intralymphnode mRNA Delivery
Lymph node (LN)-targeted mRNA vaccines hold promise for cancer immunotherapy, but their efficacy is constrained by limited parenchymal delivery imposed by the lymphatic endothelial barrier of the subcapsular sinus (SCS). The SCS is populated by macrophages that efficiently capture pathogens, raising the question of whether this innate surveillance mechanism can be repurposed for vaccine transport─provided internalized nanoparticles can be rerouted from lysosomal degradation toward transcytosis. Here, we show that yeast cell wall–coated lipid nanoparticles (YCW-LNPs) reprogram SCS macrophages to mediate efficient transcytosis, enabling active delivery into the LN parenchyma and achieving approximately 21-fold higher LN accumulation than unmodified LNPs. Co-encapsulating ovalbumin (OVA) mRNA and the STING agonist MSA-2, YCW-LNPs preferentially accumulate in LNs, drive robust mRNA expression (14.5-fold and 7.4-fold higher than free mRNA and unmodified LNPs, respectively), and concurrently activate the STING pathway to amplify antigen-specific immune responses. In intradermal and lung-metastatic B16-OVA melanoma models, YCW-LNPs achieves marked tumor inhibition (up to 99.0%), prolong survival, and induce durable immune memory protecting mice against tumor rechallenge 60 days after treatment. This pathogen-inspired strategy converts SCS macrophages from degradative sinks into active transporters, offering a generalizable platform for delivering mRNA vaccines and immunomodulators to the LN parenchyma.
- Open Access
- 3 March 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (3) , e0356725
MRI of Syrian hamsters reveals SARS-CoV-2 variant-specific neuroinflammation
SARS-CoV-2 infection causes neurological manifestations in 30%–40% of patients, with reinfection exacerbating sequelae risks. Elucidating neuroinvasion mechanisms requires optimized animal models overcoming limitations of existing systems. This study establishes the Syrian hamster as a neuroanatomically optimized model to investigate SARS-CoV-2 variant-specific neuropathogenesis. Syrian hamsters subjected to primary infection and reinfection with WH-09 and Omicron subvariants (XBB.1, BA.1, or BF.7) were investigated using multimodal MRI and histopathology. We demonstrate that SARS-CoV-2 variants exhibit strikingly differential neuroinvasive capacities following primary infection and reinfection. Notably, immune-evasive variants like XBB.1 and WH-09 induced significant, unresolved damage in olfactory-limbic regions, correlating with clinical symptoms such as hyposmia. BF.7 and BA.1 exhibited minimal neurostructural alterations in both primary and reinfection models. These variant-specific neuropathological profiles, precisely mapped via MRI-histopathology correlation, underscore the model’s utility in delineating the neurological threats posed by evolving variants. IMPORTANCE: This study demonstrates that Syrian hamsters offer advantages for modeling SARS-CoV-2 neuropathogenesis. WH-09 and XBB.1’s persistent olfactory and hippocampus damage, which was quantified through integrated MRI and histopathology, underscores the neurological threat posed by immune-evasive variants. Conversely, Omicron’s attenuated phenotype provides a blueprint for virulence-modifying interventions. This work establishes multimodal imaging in hamsters as an effective strategy for evaluating emerging viral variants.
- 3 March 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (3) , e0356725
Open AccessMRI of Syrian hamsters reveals SARS-CoV-2 variant-specific neuroinflammation
SARS-CoV-2 infection causes neurological manifestations in 30%–40% of patients, with reinfection exacerbating sequelae risks. Elucidating neuroinvasion mechanisms requires optimized animal models overcoming limitations of existing systems. This study establishes the Syrian hamster as a neuroanatomically optimized model to investigate SARS-CoV-2 variant-specific neuropathogenesis. Syrian hamsters subjected to primary infection and reinfection with WH-09 and Omicron subvariants (XBB.1, BA.1, or BF.7) were investigated using multimodal MRI and histopathology. We demonstrate that SARS-CoV-2 variants exhibit strikingly differential neuroinvasive capacities following primary infection and reinfection. Notably, immune-evasive variants like XBB.1 and WH-09 induced significant, unresolved damage in olfactory-limbic regions, correlating with clinical symptoms such as hyposmia. BF.7 and BA.1 exhibited minimal neurostructural alterations in both primary and reinfection models. These variant-specific neuropathological profiles, precisely mapped via MRI-histopathology correlation, underscore the model’s utility in delineating the neurological threats posed by evolving variants. IMPORTANCE: This study demonstrates that Syrian hamsters offer advantages for modeling SARS-CoV-2 neuropathogenesis. WH-09 and XBB.1’s persistent olfactory and hippocampus damage, which was quantified through integrated MRI and histopathology, underscores the neurological threat posed by immune-evasive variants. Conversely, Omicron’s attenuated phenotype provides a blueprint for virulence-modifying interventions. This work establishes multimodal imaging in hamsters as an effective strategy for evaluating emerging viral variants.
- 11 October 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (11) , 4956-4964
Signal Amplification Pretargeted PET/Fluorescence Imaging Based on Human Serum Albumin-Encapsulated GdF3 Nanoparticles for Diagnosis of Ovarian Cancer
Different modal imaging techniques could be complementary in tumor diagnosis. Human serum albumin (HSA)-encapsulated GdF3 nanoparticles were developed as T1 magnetic resonance imaging (MRI) contrast agents. However, no significant T1 enhancement in the tumor site of the SKOV3 human ovarian cancer xenograft tumor model was observed within 3 h after injection of tetrazine-modified GdF3@HSA NPs through small-animal MRI. After intravenous injection of 18F (or Cy7)-labeled Reppe anhydride, pretargeted positron emission tomog-raphy (PET) (near-infrared (NIR) fluorescence) imaging was used to reveal the pharmacokinetics of GdF3@HSA NPs in the SKOV3 xenograft mouse model to locate the tumor. The probe based on Reppe anhydride achieved rapid ligation with tetrazine-modified GdF3@HSA nanoparticles (NPs), which accumulated in tumor through Reppe anhydride/tetrazine bioorthogonal chemistry. This pretargeting strategy enabled excellent tumor visualization and quantification at an early period after nanoparticle injection (3 h p.i.), while the MRI images with significant T1 enhancement could be obtained until 24 h after injection of Gd-based contrast agents only. In vivo pretargeted multimodal imaging based on the tetrazine/Reppe anhydride system using HSA-encapsulated GdF3 nanoparticles would be beneficial for amplification of the imaging signal in the disease site and enhancing diagnostic efficiency.
- 11 October 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (11) , 4956-4964
Signal Amplification Pretargeted PET/Fluorescence Imaging Based on Human Serum Albumin-Encapsulated GdF3 Nanoparticles for Diagnosis of Ovarian Cancer
Different modal imaging techniques could be complementary in tumor diagnosis. Human serum albumin (HSA)-encapsulated GdF3 nanoparticles were developed as T1 magnetic resonance imaging (MRI) contrast agents. However, no significant T1 enhancement in the tumor site of the SKOV3 human ovarian cancer xenograft tumor model was observed within 3 h after injection of tetrazine-modified GdF3@HSA NPs through small-animal MRI. After intravenous injection of 18F (or Cy7)-labeled Reppe anhydride, pretargeted positron emission tomog-raphy (PET) (near-infrared (NIR) fluorescence) imaging was used to reveal the pharmacokinetics of GdF3@HSA NPs in the SKOV3 xenograft mouse model to locate the tumor. The probe based on Reppe anhydride achieved rapid ligation with tetrazine-modified GdF3@HSA nanoparticles (NPs), which accumulated in tumor through Reppe anhydride/tetrazine bioorthogonal chemistry. This pretargeting strategy enabled excellent tumor visualization and quantification at an early period after nanoparticle injection (3 h p.i.), while the MRI images with significant T1 enhancement could be obtained until 24 h after injection of Gd-based contrast agents only. In vivo pretargeted multimodal imaging based on the tetrazine/Reppe anhydride system using HSA-encapsulated GdF3 nanoparticles would be beneficial for amplification of the imaging signal in the disease site and enhancing diagnostic efficiency.
- 6 November 2020
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 31 (11) , 2576-2584
Multifunctional Transferrin Encapsulated GdF3 Nanoparticles for Sentinel Lymph Node and Tumor Imaging
The transferrin encapsulated GdF3 nanoparticles have been fabricated via biomineralization method. The obtained GdF3@Tf NPs show an attractive T2MRI and CT enhancement effect. Furthermore, PET and NIR imaging capacity are integrated into nanoparticles through conjugating with radionuclide 64Cu and fluorescent dye Cy7. 64Cu-GdF3@Tf-Cy7 NPs are developed and applied in small animal multimodal imaging in vivo. Compared with the previous multimodal imaging agents, 64Cu-GdF3@Tf-Cy7 NPs enable not only precise sentinel lymph node (SLN) identification, but specific imaging for transferrin receptor overexpressed colorectal tumor in vivo. The results reveal that 64Cu-GdF3@Tf-Cy7 NPs are potential and efficient multimodal imaging agents for SLN and tumor preclinical imaging.
- 6 November 2020
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 31 (11) , 2576-2584
Multifunctional Transferrin Encapsulated GdF3 Nanoparticles for Sentinel Lymph Node and Tumor Imaging
The transferrin encapsulated GdF3 nanoparticles have been fabricated via biomineralization method. The obtained GdF3@Tf NPs show an attractive T2MRI and CT enhancement effect. Furthermore, PET and NIR imaging capacity are integrated into nanoparticles through conjugating with radionuclide 64Cu and fluorescent dye Cy7. 64Cu-GdF3@Tf-Cy7 NPs are developed and applied in small animal multimodal imaging in vivo. Compared with the previous multimodal imaging agents, 64Cu-GdF3@Tf-Cy7 NPs enable not only precise sentinel lymph node (SLN) identification, but specific imaging for transferrin receptor overexpressed colorectal tumor in vivo. The results reveal that 64Cu-GdF3@Tf-Cy7 NPs are potential and efficient multimodal imaging agents for SLN and tumor preclinical imaging.
- Open Access
- 14 March 2019
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 4 (3) , 5310-5316
64Cu-Based Pretargeted Immuno-Positron Emission Tomography and Near-Infrared Fluorescence Imaging of the Vascular Endothelial Growth Factor
Pretargeted immuno-positron emission tomography (PET)/near-infrared fluorescence (NIRF) using bioorthogonal chemistry between radioisotope- or fluorophore-labeled Reppe anhydrides and vascular endothelial growth factor (VEGF)-specific monoclonal antibody bevacizumab–tetrazine conjugates was developed. The pretargeting approach provided a high target-to-background contrast. An in vivo investigation clearly indicated the suitability of the 64Cu-radiolabeled Reppe anhydride for pretargeted PET imaging of VEGF-expressing colorectal tumors. The radiation exposure to healthy tissues decreased as a result of the rapid elimination of the PET probe. Pretargeted NIRF imaging was also used to visualize the VEGF expression in HCT116 tumors using bevacizumab–tetrazine/cyanine 5-labeled Reppe anhydride chemistry.
- 14 March 2019
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 4 (3) , 5310-5316
Open Access64Cu-Based Pretargeted Immuno-Positron Emission Tomography and Near-Infrared Fluorescence Imaging of the Vascular Endothelial Growth Factor
Pretargeted immuno-positron emission tomography (PET)/near-infrared fluorescence (NIRF) using bioorthogonal chemistry between radioisotope- or fluorophore-labeled Reppe anhydrides and vascular endothelial growth factor (VEGF)-specific monoclonal antibody bevacizumab–tetrazine conjugates was developed. The pretargeting approach provided a high target-to-background contrast. An in vivo investigation clearly indicated the suitability of the 64Cu-radiolabeled Reppe anhydride for pretargeted PET imaging of VEGF-expressing colorectal tumors. The radiation exposure to healthy tissues decreased as a result of the rapid elimination of the PET probe. Pretargeted NIRF imaging was also used to visualize the VEGF expression in HCT116 tumors using bevacizumab–tetrazine/cyanine 5-labeled Reppe anhydride chemistry.
- 18 January 2018
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (2) , 250-254
Pretargeted Immuno-PET Based on Bioorthogonal Chemistry for Imaging EGFR Positive Colorectal Cancer
Pretargeted immuno-PET imaging based on the bioorthogonal chemistry between 18F-labeled Reppe anhydride derivatives and tetrazine conjugates of the EGFR-specific monoclonal antibodies cetuximab and panitumumab was performed. This pretargeting approach yielded high target-to-nontarget ratios. Furthermore, due to the fast clearance rate of the PET probe, the overall radiation burden to nontarget tissues was also substantially decreased.
- 18 January 2018
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (2) , 250-254
Pretargeted Immuno-PET Based on Bioorthogonal Chemistry for Imaging EGFR Positive Colorectal Cancer
Pretargeted immuno-PET imaging based on the bioorthogonal chemistry between 18F-labeled Reppe anhydride derivatives and tetrazine conjugates of the EGFR-specific monoclonal antibodies cetuximab and panitumumab was performed. This pretargeting approach yielded high target-to-nontarget ratios. Furthermore, due to the fast clearance rate of the PET probe, the overall radiation burden to nontarget tissues was also substantially decreased.